Wee Joo Chng
YOU?
Author Swipe
View article: USP13 dictates Ran turnover and vulnerability to ferroptosis in diffuse large B cell lymphoma (DLBCL)
USP13 dictates Ran turnover and vulnerability to ferroptosis in diffuse large B cell lymphoma (DLBCL) Open
Diffuse large B-cell lymphoma (DLBCL) is one of the most common and lethal B-cell malignancies worldwide, with high relapse rate after standard treatment, and the relapsed cases are often difficult to treat. Ubiquitination has a pivotal ro…
View article: Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)
Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003) Open
Pomalidomide has been shown to improve survival in patients with relapsed/refractory myeloma (RRMM). However, the optimal pomalidomide-based combinations in RRMM are not known. This study compared pomalidomide, cyclophosphamide, dexamethas…
View article: Perspectives on Anti-BCMA Bispecific Antibodies use in Multiple Myeloma–Experience from Asian Countries
Perspectives on Anti-BCMA Bispecific Antibodies use in Multiple Myeloma–Experience from Asian Countries Open
The insights gained will contribute to developing strategic frameworks and consensus guidelines that can effectively guide clinicians in optimizing outcomes for myeloma patients in diverse healthcare settings.
View article: Singapore Myeloma Study Group consensus guidelines for the management of patients with newly diagnosed multiple myeloma
Singapore Myeloma Study Group consensus guidelines for the management of patients with newly diagnosed multiple myeloma Open
Multiple myeloma (MM) is the second most common haematologic malignancy and remains incurable. Significant advances have been made in both supportive care and definitive therapy for MM, leading to marked improvements in survival and qualit…
View article: MyeVAE: a multi-modal variational autoencoder for risk profiling of newly diagnosed multiple myeloma
MyeVAE: a multi-modal variational autoencoder for risk profiling of newly diagnosed multiple myeloma Open
Background There is a need for more accurate prognosis in multiple myeloma given the current heterogeneity in survival outcomes. In other cancers, the self-complementary nature of multi-omics is driving to the adoption of multi-omics data …
View article: Deceased donor kidney transplantation in candidates with pre-transplant hematological malignancies: a literature review and recipient allocation proposal in Singapore
Deceased donor kidney transplantation in candidates with pre-transplant hematological malignancies: a literature review and recipient allocation proposal in Singapore Open
Deceased donor kidneys are a scarce national resource, and principles of utilitarianism and justice govern allocation. Kidney transplant recipients with a prior history of cancer show an increased risk of malignancy- and non-malignancy-rel…
View article: Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group
Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group Open
Anti-CD38 monoclonal antibodies (mAbs), including daratumumab and isatuximab, have become key components of treatment for relapsed/refractory multiple myeloma (RRMM). This expert consensus provides evidence-based guidance on their optimal …
View article: A clinico-genomic prognostic model for primary myelodysplastic neoplasm in Asia
A clinico-genomic prognostic model for primary myelodysplastic neoplasm in Asia Open
A personalized prognostic model that takes into account the unique molecular features of primary myelodysplastic neoplasm (MDS) in Asia patients is lacking. Diagnostic clinicopathologic features, cytogenetic changes, and gene mutations of …
View article: Proliferative CD8 T-cells : A Novel Immune Microenvironmental Determinant of Outcomes in Multiple Myeloma
Proliferative CD8 T-cells : A Novel Immune Microenvironmental Determinant of Outcomes in Multiple Myeloma Open
Multiple myeloma (MM) remains incurable despite major therapeutic advances, and the tumor microenvironment (TME) plays an important role in disease progression. Since T-cell dysfunction is of particular importance in MM, we hypothesised th…
View article: Deciphering the dynamics of histone acetylation and chromatin remodeling in multiple myeloma: a tale beyond the tails
Deciphering the dynamics of histone acetylation and chromatin remodeling in multiple myeloma: a tale beyond the tails Open
The development of multiple myeloma is typically associated with various cytogenetic abnormalities; however, these genetic changes alone do not fully account for the observed heterogeneity in patient prognosis and treatment response. Recen…
View article: A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM)
A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM) Open
NCT03153036.
View article: Novel NUDCD1 gene variant predisposes to severe COVID-19 disease in Asians through modulation of antiviral DHX15- and MAVS-mediated signalling
Novel NUDCD1 gene variant predisposes to severe COVID-19 disease in Asians through modulation of antiviral DHX15- and MAVS-mediated signalling Open
Background Genome-wide associative studies can potentially uncover novel pathways which modulate anti-viral immune responses against SARS-CoV-2 or identify drivers of severe disease. To date, these studies have yielded loci mostly in non-f…
View article: Imaging in plasma cell disorders—consensus recommendations of the Asian myeloma network bone imaging workgroup
Imaging in plasma cell disorders—consensus recommendations of the Asian myeloma network bone imaging workgroup Open
The role of imaging in accurate classification and management of plasma cell disorders is substantial with the increasing evidence in the ability of cross-sectional imaging to identify disease related manifestations. International myeloma …
View article: c-MYC can Form Phase Condensates via its DNA Binding Domain
c-MYC can Form Phase Condensates via its DNA Binding Domain Open
The c-MYC oncogene is overexpressed in cancers. Phase condensates are membrane-less cellular compartments in cells. Using the optoDroplet system, which leverages optogenetics for condensate dynamics studies, here we showed c-MYC has the ca…
View article: Treatment pathways and clinical outcomes in newly diagnosed multiple myeloma outside Europe and North America: The INTEGRATE study
Treatment pathways and clinical outcomes in newly diagnosed multiple myeloma outside Europe and North America: The INTEGRATE study Open
Background Real-world data on multiple myeloma (MM) outside Europe and North America are limited. The INTEGRATE study retrospectively assessed real-world treatment pathways and outcomes in MM from Argentina, China, South Korea, South Afric…
View article: Consensus Guidelines and Recommendations for The CD38 Monoclonal Antibody-based Quadruplet Therapy and Management in Clinical Practice for Newly Diagnosed Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group
Consensus Guidelines and Recommendations for The CD38 Monoclonal Antibody-based Quadruplet Therapy and Management in Clinical Practice for Newly Diagnosed Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group Open
The therapeutic outcomes of clinical trials for incorporating anti-CD38 monoclonal antibodies (including isatuximab and daratumumab) into the bortezomib/lenalidomide/dexamethasone (VRd) triplet therapy backbone as the first-line treatment …
View article: A systematic benchmark of Nanopore long-read RNA sequencing for transcript-level analysis in human cell lines
A systematic benchmark of Nanopore long-read RNA sequencing for transcript-level analysis in human cell lines Open
The human genome contains instructions to transcribe more than 200,000 RNAs. However, many RNA transcripts are generated from the same gene, resulting in alternative isoforms that are highly similar and that remain difficult to quantify. T…
View article: A Chk1-Sp1-CD59 axis of the DNA damage response impedes rituximab-mediated complement-dependent cytotoxicity
A Chk1-Sp1-CD59 axis of the DNA damage response impedes rituximab-mediated complement-dependent cytotoxicity Open
DNA damage responses primarily coordinate intracellular processes, but their effects on the cell surface remain poorly understood. We uncovered a DNA damage response at the cell surface that regulates complement dependent cytotoxicity (CDC…
View article: Matching-Adjusted Indirect Comparison of Daratumumab-Pomalidomide-Dexamethasone and Pomalidomide-Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma
Matching-Adjusted Indirect Comparison of Daratumumab-Pomalidomide-Dexamethasone and Pomalidomide-Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Open
This analysis suggests that DPd improves PFS and might improve OS versus PVd in patients with RRMM. Additional evidence from head-to-head trials or real-world patient databases are warranted to confirm these results.
View article: International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma Open
T-cell redirecting therapy (TCRT), specifically chimeric antigen receptor T-cell therapy (CAR T-cells) and bispecific T-cell engagers (TCEs) represent a remarkable advance in the treatment of multiple myeloma (MM). There are several produc…
View article: EZH2 modulates mRNA splicing and exerts part of its oncogenic function through repression of splicing factors in CML
EZH2 modulates mRNA splicing and exerts part of its oncogenic function through repression of splicing factors in CML Open
The polycomb protein EZH2 is up-regulated in Chronic Myeloid Leukaemia (CML) and associated with transcriptional reprogramming. Here we tested whether EZH2 might also act as a modulator of the mRNA splicing landscape to elicit its oncogeni…